1-3 of 3
Jian-kang Jiang
Close
Sort by
Journal Articles

Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML

Katelyn Melgar, MacKenzie Walker, Jian-kang Jiang, PhD, Kelli Wilson, PhD, James C. Mulloy, PhD, Craig J Thomas, PhD, Daniel T Starczynowski, PhD
Journal: Blood
Blood (2015) 126 (23): 3690.
https://doi.org/10.1182/blood.V126.23.3690.3690
Published: 2015
Journal Articles

Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK–mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma

Scott R. P. McDonnell, Steven R. Hwang, Delphine Rolland, Carlos Murga-Zamalloa, Venkatesha Basrur, Kevin P. Conlon, Damian Fermin, Thomas Wolfe, Alexander Raskind, Chunhai Ruan, Jian-Kang Jiang, Craig J. Thomas, Cory M. Hogaboam, Charles F. Burant, Kojo S. J. Elenitoba-Johnson, Megan S. Lim
Journal: Blood
Blood (2013) 122 (6): 958–968.
https://doi.org/10.1182/blood-2013-01-482026
Published: 2013
Includes: Supplemental data
Journal Articles

CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP

Wei Ju, Meili Zhang, Jian-kang Jiang, Craig J. Thomas, Unsong Oh, Bonita R. Bryant, Jing Chen, Noriko Sato, Yutaka Tagaya, John C. Morris, John E. Janik, Steven Jacobson, Thomas A. Waldmann
Journal: Blood
Blood (2011) 117 (6): 1938–1946.
https://doi.org/10.1182/blood-2010-09-305425
Published: 2011
Includes: Supplemental data